These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria. Miocinovic R; Jones JS; Pujara AC; Klein EA; Stephenson AJ Urology; 2011 Apr; 77(4):980-4. PubMed ID: 21256549 [TBL] [Abstract][Full Text] [Related]
24. How to define cumulative cancer length for selecting candidate for active surveillance? Russo GI; Morgia G J Clin Pathol; 2015 May; 68(5):323-4. PubMed ID: 25770160 [No Abstract] [Full Text] [Related]
26. Watchful Waiting-Active Surveillance in Low-Risk Prostate Cancer-Reply. Williams SB; Chamie K; Hu JC JAMA Oncol; 2015 Aug; 1(5):689-90. PubMed ID: 26181144 [No Abstract] [Full Text] [Related]
27. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Soloway MS; Soloway CT; Eldefrawy A; Acosta K; Kava B; Manoharan M Eur Urol; 2010 Dec; 58(6):831-5. PubMed ID: 20800964 [TBL] [Abstract][Full Text] [Related]
28. The inconveniences of active surveillance in prostate cancer. Sánchez-de-Badajoz E Actas Urol Esp; 2016 Mar; 40(2):69-71. PubMed ID: 26341888 [No Abstract] [Full Text] [Related]
29. Economic analysis of active surveillance for localized prostate cancer. Kim S; Dall'Era MA; Evans CP Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666 [TBL] [Abstract][Full Text] [Related]
30. [Active surveillance of prostatic cancer]. Vasarainen H; Ruutu M; Rannikko A Duodecim; 2011; 127(6):593-9. PubMed ID: 21528523 [TBL] [Abstract][Full Text] [Related]
32. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. Vellekoop A; Loeb S; Folkvaljon Y; Stattin P J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481 [TBL] [Abstract][Full Text] [Related]
33. To treat or not to treat: is the way forward clearer in low-risk prostate cancer? Gnanapragasam VJ BJU Int; 2013 Aug; 112(3):285-7. PubMed ID: 23469893 [No Abstract] [Full Text] [Related]
34. Expectant management for men with early stage prostate cancer. Filson CP; Marks LS; Litwin MS CA Cancer J Clin; 2015; 65(4):265-82. PubMed ID: 25958817 [TBL] [Abstract][Full Text] [Related]
35. The Prostate cancer Research International: Active Surveillance study. Bangma CH; Bul M; Roobol M Curr Opin Urol; 2012 May; 22(3):216-21. PubMed ID: 22453333 [TBL] [Abstract][Full Text] [Related]
36. A multi-institutional evaluation of active surveillance for low risk prostate cancer. Eggener SE; Mueller A; Berglund RK; Ayyathurai R; Soloway C; Soloway MS; Abouassaly R; Klein EA; Jones SJ; Zappavigna C; Goldenberg L; Scardino PT; Eastham JA; Guillonneau B J Urol; 2013 Jan; 189(1 Suppl):S19-25; discussion S25. PubMed ID: 23234624 [TBL] [Abstract][Full Text] [Related]
37. [Watchful waiting in incidental adenocarcinoma of the prostate]. Morán Pascual E; Dicapua Sacoto C; Trassierra Villa M; Pontones Moreno JL; Ruiz Cerdá JL; Jiménez Cruz JF Actas Urol Esp; 2010 Nov; 34(10):854-9. PubMed ID: 21159280 [TBL] [Abstract][Full Text] [Related]
38. [Prostatectomy vs. "watchful waiting" in early prostate cancer]. Markun S Praxis (Bern 1994); 2014 Jul; 103(15):909-10. PubMed ID: 25051936 [No Abstract] [Full Text] [Related]
39. Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance. Trock BJ Curr Opin Urol; 2014 May; 24(3):293-302. PubMed ID: 24710054 [TBL] [Abstract][Full Text] [Related]
40. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Gallina A Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]